US Patent

US10821074 — Sublingual and buccal film compositions

Formulation · Assigned to Aquestive Therapeutics Inc · Expires 2029-08-07 · 3y remaining

Vulnerability score 48/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects sublingual and buccal film compositions that provide an active agent while adhering to the buccal area.

USPTO Abstract

The present invention relates to products and methods for treatment of various symptoms in a patient, including treatment of pain suffered by a patient. The invention more particularly relates to self-supporting dosage forms which provide an active agent while providing sufficient buccal adhesion of the dosage form. Further, the present invention provides a dosage form which is useful in reducing the likelihood of diversion abuse of the active agent.

Drugs covered by this patent

Patent Metadata

Patent number
US10821074
Jurisdiction
US
Classification
Formulation
Expires
2029-08-07
Drug substance claim
No
Drug product claim
Yes
Assignee
Aquestive Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.